A Phase 3 interventional study of Drug: AC-170 0.24% and AC-170 0% in Atopic Disease (Including Allergic Conjunctivitis), sponsored by Aciex Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2017-09-11.
Sponsored by Aciex Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 5th largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2014, is one of 34 in phase 3, and was the 60th registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
Browse Conjunctivitis, Allergic studies →6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 8+
Dompé Farmaceutici S.p.A · Sites in United States, Argentina, Czechia and 11 more countries
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 29 · Phase 3 36 · Phase 4 20
First in 2000; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 512 is above the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 94 across the 90 interventional studies, 100 across the 5 observational. Of the 84 that completed or were terminated, 50 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 95 have an industry lead sponsor. The 10 most frequent:
Aciex Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Aciex Therapeutics, Inc. has 6 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
1 of the studies in Conjunctivitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938632Telios Pharma, Inc.TL-925 for the Treatment of Allergic Conjunctivitis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Drug: AC-170 0.24%
Drug: AC-170 0%
Also known as: 1 drop in each eye 2 times daily for up to 6 weeks
Also known as: 1 drop in each eye 2 times daily for up to 6 weeks
Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 1 (Day 1)
Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.
Time frame: Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation
Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 2 (Day 8)
Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.
Time frame: Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation
Tolerability of AC 170 0.24% Compared to Its Vehicle at Visit 3 (Day 22)
Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.
Time frame: Upon instillation, 30 Seconds Post-Instillation, 1 minute Post-Instillation
Safety of AC 170 0.024% Compared to Its Vehicle
Safety measures (adverse events) of AC 170 0.024% compared to its vehicle were measured at Visit 1-4 and 5 (for subset of patients).
Time frame: Up to 12 Weeks
Subjects were recruited from four sites in the US.
| Milestone | AC-170 0.24% | AC-170 0% |
|---|---|---|
| Started | 341 | 171 |
| Completed | 326 | 162 |
| Not completed | 15 | 9 |
Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| Upon instillation | 0.9 ± 1.36 | 0.5 ± 1.02 |
| 30 seconds post-instillation | 0.7 ± 1.25 | 0.3 ± 0.82 |
| 1 minute post-instillation | 0.6 ± 1.22 | 0.3 ± 0.75 |
Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| Upon instillation | 0.8 ± 1.24 | 0.3 ± 0.80 |
| 30 seconds post-instillation | 0.5 ± 1.02 | 0.3 ± 0.74 |
| 1 minute post-instillation | 0.4 ± 0.90 | 0.2 ± 0.63 |
Tolerability was assessed upon instillation of study medication, at 30 seconds and 1 minute post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| Upon instillation | 0.6 ± 1.13 | 0.2 ± 0.66 |
| 30 seconds post-instillation | 0.4 ± 0.83 | 0.2 ± 0.51 |
| 1 minute post-instillation | 0.3 ± 0.80 | 0.1 ± 0.47 |
Safety measures (adverse events) of AC 170 0.024% compared to its vehicle were measured at Visit 1-4 and 5 (for subset of patients).
| adverse events | AC-170 0.24% | AC-170 0% |
|---|---|---|
| Safety of AC 170 0.024% Compared to Its Vehicle | 70 | 40 |
Collected over Adverse events were collected for the duration of the study. All subjects who received study medication were evaluable for the safety analysis.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AC-170 0.24% | — | 1/341 (0.3%) | 65/341 (19.1%) |
| AC-170 0% | — | 1/171 (0.6%) | 39/171 (22.8%) |
| Event | AC-170 0.24% | AC-170 0% |
|---|---|---|
| Anaphylactic shockImmune system disorders | 0/341 | 1/171 |
| Herpes zosterInfections and infestations | 1/341 | 0/171 |
| Event | AC-170 0.24% | AC-170 0% |
|---|---|---|
| Conjunctival HyperaemiaEye disorders | 27/341 | 19/171 |
| Instillation Site PainGeneral disorders | 20/341 | 3/171 |
| Ocular HyperaemiaEye disorders | 10/341 | 3/171 |
| Vision BlurredEye disorders | 2/341 | 3/171 |
| Dry eyeEye disorders | 1/341 | 3/171 |
| Visual acuity reducedEye disorders | 2/341 | 2/171 |
| Eye dischargeEye disorders | 1/341 | 2/171 |
| HeadacheNervous system disorders | 2/341 | 2/171 |
| DizzinessNervous system disorders | 0/341 | 2/171 |
| Age, Continuous(years) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| Mean | 34.9 ± 19.36 | 36.6 ± 19.56 | 35.4 ± 19.42 |
| Age, Customized(participants) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| 2-6 years old | 20 | 13 | 33 |
| 7-12 years old | 28 | 12 | 40 |
| 13-17 years old | 34 | 16 | 50 |
| >/= 18 years old | 259 | 130 | 389 |
| Sex: Female, Male(Participants) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| Female | 195 | 114 | 309 |
| Male | 146 | 57 | 203 |
| Ethnicity (NIH/OMB)(Participants) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| Hispanic or Latino | 20 | 11 | 31 |
| Not Hispanic or Latino | 321 | 160 | 481 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 2 | 5 |
| Asian | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 23 | 14 | 37 |
| White | 298 | 149 | 447 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 14 | 4 | 18 |
| Region of Enrollment(participants) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| United States | 341 | 171 | 512 |
The record gives a start of May 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 2 years 9 months after primary completion. A results delay was requested in Apr 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetirizine
Aciex Therapeutics, Inc.